TLDR
- CMS finalized 2027 Medicare Advantage payment policies, projecting a net average 2.48% increase — over $13 billion in additional payments
- CVS stock rose as much as 5.20% Tuesday, with the Aetna insurance unit seen as a direct beneficiary
- CMS will continue using the 2024 risk-adjustment model for 2027, with tighter rules around unlinked chart review diagnoses
- Cantor Fitzgerald reiterated an Overweight rating with a $95 price target, citing Medicare Advantage margin recovery as a key driver
- CVS next reports earnings on May 6, with EPS estimated at $2.23 and revenue at $94.86 billion
CVS Health posted one of its better days in recent memory on Tuesday, driven by a Medicare Advantage policy update that sent managed-care names broadly higher.
The Centers for Medicare & Medicaid Services finalized its 2027 Medicare Advantage and Part D payment rules, projecting a net average increase of 2.48% — translating to more than $13 billion in additional funding across the sector for calendar year 2027.
For CVS, that’s not a minor footnote. Through its Aetna unit, the company carries real exposure to Medicare Advantage, alongside its pharmacy benefit manager and retail pharmacy operations.
The market read the headline number as a positive. CVS stock climbed as much as 5.20% in Tuesday morning trading.
Risk-Adjustment Rules Add Some Complexity
The update wasn’t entirely straightforward. CMS confirmed it will stick with the 2024 risk-adjustment model for 2027, and will exclude diagnoses from unlinked chart reviews in most risk-score calculations.
That’s a tighter standard that could affect insurers who leaned on coding-driven reimbursement strategies. For CVS, which runs a diversified operation, traders appeared to focus more on the funding increase than the risk-adjustment fine print.
The Stars ratings picture has also been improving for CVS. Its bonus-eligible Stars scores dropped sharply from 85% in 2022 to 21% in 2023 — a period that weighed heavily on Medicare Advantage margins.
Cantor Fitzgerald, which reiterated an Overweight rating with a $95 price target on Monday, said the Medicare Advantage unit still has further to go to reach 3% margins, but estimated that 2026 individual Medicare Advantage margins are slightly profitable.
The stock was trading at $73.28 before Tuesday’s move, a level Cantor and others view as undervalued relative to fair value.
Analysts Stay Bullish, Eye May 6 Earnings
The analyst community has largely maintained a constructive stance on CVS. The stock carries a consensus Buy rating with an average price target of $92.79.
Recent moves include Bernstein upgrading to Outperform with a $94 target in March, Piper Sandler holding Overweight while trimming its target to $99, and Argus Research maintaining a Buy at $90.
Leerink Partners also holds an Outperform with a $98 target, a view shaped in part by the recent FTC consent agreement involving Caremark and Zinc, which the firm saw as removing a layer of regulatory uncertainty.
On the corporate side, CVS recently announced an asset purchase agreement with GenieRx Holdings, positioning GenieRx as the stalking horse bidder in Omnicare’s court-supervised sale process.
The company also appointed John E. Gallina, formerly CFO at Elevance Health, to its board of directors and audit committee.
Next up: CVS reports Q1 2026 earnings on May 6. The Street is looking for EPS of $2.23 and revenue of $94.86 billion.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
